Cellmat Therapeutics "Lost Lawsuit on Invalidity of eTrial New Share Issuance"

[Asia Economy Reporter Choi Dae-yeol] Cellmat Therapeutics confirmed on the 1st that although it acquired 2 million shares through Etrial's paid-in capital increase in June this year, the plaintiff won the lawsuit filed by the company's shareholder seeking invalidation of the new share issuance.